# Effects of Spironolactone Combination Therapy on Proteinuria, Kidney Function, and Blood Pressure

Study · id `cardio:ct-nct01667614` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01667614](<https://clinicaltrials.gov/study/NCT01667614>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01667614

Browse, organ or system: Blood vessels; Kidneys; Metabolism  
Browse, condition area: High blood pressure; Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 136 participants.

## Technical summary

Registry record NCT01667614. Randomized; no masking; primary purpose treatment. Start 2010-05 (registry gives no type); primary completion 2012-03 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 136 participants (enrolled count; ClinicalTrials.gov record NCT01667614, source copy `cardio:ctgov-nct01667614-2012-08-28`, retrieved 2026-10-26)
- Start date: 2010-05 (registry gives no type) (ClinicalTrials.gov record NCT01667614, source copy `cardio:ctgov-nct01667614-2012-08-28`, retrieved 2026-10-26)
- Primary completion: 2012-03 (actual) (ClinicalTrials.gov record NCT01667614, source copy `cardio:ctgov-nct01667614-2012-08-28`, retrieved 2026-10-26)
- Completion: 2012-07 (actual) (ClinicalTrials.gov record NCT01667614, source copy `cardio:ctgov-nct01667614-2012-08-28`, retrieved 2026-10-26)
- Countries: Iran (ClinicalTrials.gov record NCT01667614, source copy `cardio:ctgov-nct01667614-2012-08-28`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01667614-2012-08-28`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effects of Spironolactone Combination Therapy on Proteinuria, Kidney Function, and Blood Pressure
- Condition: Type 2 Diabetes Mellitus
- Condition: Diabetic Nephropathy
- Condition: Essential Hypertension
- Intervention (Drug): spironolacone 25 mg tablets added to losartan
- Lead sponsor: Tehran University of Medical Sciences
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Diabetic kidney disease (`cardio:diabetic-nephropathy`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Tehran University of Medical Sciences (`cardio:org-tehran-university-of-medical-sciences`)

## Provenance

Content hash: 451055bcd831737052c04e7f16663cd3900e3fa07da3485efd4cceb150126fac
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
